Canaccord Genuity Reiterates a 'Buy' on OraSure Technologies (OSUR); HIV-OTC Timeline May Improve
Tweet
Share
E-mailGet Alerts OSUR Hot Sheet
Price: $3.88 +3.74%
Rating Summary:
9 Buy, 8 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Rating Summary:
9 Buy, 8 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Join SI Premium – FREE
Canaccord Genuity reiterates a 'Buy' on OraSure Technologies (NASDAQ: OSUR) price target of $10.00.
Canaccord analyst, Jeffrey Frelick, said, "We reiterate our rating on OSUR following time spent recently with management that not only reinforced our investment thesis but the possibility that the HIV-OTC commercialization timeline for YE/2012 could accelerate next year."
For more ratings news on OraSure Technologies click here and for the rating history of OraSure Technologies click here.
Shares of OraSure Technologies closed at $7.27 yesterday.
Canaccord analyst, Jeffrey Frelick, said, "We reiterate our rating on OSUR following time spent recently with management that not only reinforced our investment thesis but the possibility that the HIV-OTC commercialization timeline for YE/2012 could accelerate next year."
For more ratings news on OraSure Technologies click here and for the rating history of OraSure Technologies click here.
Shares of OraSure Technologies closed at $7.27 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Advance Auto Parts (AAP) PT Lowered to $48 at DA Davidson Following 25% Selloff Post Q2 Results
- Clear Street Reiterates Buy Rating on Anterix Inc. (ATEX)
- Deere (DE) PT Raised to $585 at JPMorgan
Create E-mail Alert Related Categories
Analyst CommentsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
